Browse by Series:

Overcoming Acquired Resistance Mechanisms in BRAF+ mCRC

Insights From: Scott Kopetz, MD, PhD, FACP, The University of Texas MD Anderson Cancer Center; Ryan Corcoran, MD, PhD, Massachusetts General Hospital Cancer Center
Published: Thursday, Jan 31, 2019



Following their discussion on data from the BEACON and ANCHOR trials, experts look towards the future and the potential of overcoming acquired resistance mechanisms in the treatment of BRAF-mutated metastatic colorectal cancer.
SELECTED
LANGUAGE
Slider Left
Slider Right


Following their discussion on data from the BEACON and ANCHOR trials, experts look towards the future and the potential of overcoming acquired resistance mechanisms in the treatment of BRAF-mutated metastatic colorectal cancer.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x